2025-524367-20-00招募中2 期
An open-label, single-arm extension study to evaluate the long-term safety, tolerability, and efficacy of KL1333 (napazimone) in patients with primary mitochondrial disease
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 状态
- 招募中
- 入组人数
- 96
- 试验地点
- 35
- 主要终点
- All safety parameters (including AEs, physical examination, vital signs, ECG, C-SSRS, and safety laboratory [hematology, blood chemistry, and urinalysis]).
研究概览
简要总结
To study the safety and tolerability of 48 weeks of open-label KL1333 treatment in subjects previously treated with KL1333 or placebo in the FALCON study.
入排标准
- 年龄范围
- 18 years 至 65+ years（18-64 Years, 65+ Years）
- 接受健康志愿者
- 否
入选标准
- •Completed the FALCON study (age 18 years or older) and, in the opinion of the investigator and Sponsor, has been compliant with the study requirements.
- •Female subjects must agree to not donate ova throughout the study period and for 36 days after the last dose of IMP administration, and male subjects must agree to not donate sperm throughout the study period and for 96 days after the last dose of IMP administration.
- •Willingness and ability to provide informed consent.
- •Willingness and ability to attend study appointments within the specified time windows.
- •Willingness and ability to complete electronic patient-reported outcomes (ePROs).
- •Concomitant medications likely to remain stable throughout participation in the study where clinically possible.
- •Willingness to continue suspension of idebenone during the study.
- •Female subject is not pregnant and at least one of the following conditions apply: a. Not a woman of childbearing potential (WOCBP) b. WOCBP must agree not to try and become pregnant and use a highly effective method of contraception from the time of informed consent through at least 36 days (~5 half-lives of KL1333 plus 30 days) after the last dose of IMP administration.
- •Male subjects with female partner(s) of childbearing potential must agree to use a male condom in addition to using highly effective contraception throughout the treatment period and for 96 days after the last dose of IMP administration. The requirement to use a male condom also applies to male subjects with a pregnant or breastfeeding partner.
- •Female subjects must agree not to breastfeed throughout the study period and for 36 days after the last dose of IMP administration.
排除标准
- •The subject is, in the investigator’s opinion, unlikely to comply with the protocol, e.g., due to cognitive impairment, or is unsuitable for any reason.
- •Subjects not enrolling directly at the FALCON study completion visit (FALCON Week 48) or the safety follow-up visit (FALCON Week 53) study will be required to fulfill the additional exclusion criteria below during the screening visit:
- •Use of idebenone within 14 days prior to the first dose.
- •Subjects not enrolling directly at the FALCON study completion visit (FALCON Week 48) or the safety follow-up visit (FALCON Week 53) study will be required to fulfill the additional exclusion criteria below during the screening visit:
- •Subjects have a history of unstable or severe pulmonary, immunological, oncological, hepatic disease, renal disease, or another medically significant illness other than PMD or takes medication that could, in the investigator’s opinion, interfere with the assessments of safety, tolerability, or efficacy, or interfere with the conduct or interpretation of the study.
- •Subjects not enrolling directly at the FALCON study completion visit (FALCON Week 48) or the safety follow-up visit (FALCON Week 53) study will be required to fulfill the additional exclusion criteria below during the screening visit:
- •Female subjects with a positive pregnancy result at screening.
- •Subjects not enrolling directly at the FALCON study completion visit (FALCON Week 48) or the safety follow-up visit (FALCON Week 53) study will be required to fulfill the additional exclusion criteria below during the screening visit:
- •A subject cannot participate if they received an investigational drug 30 days or 5 half lives prior to the screening visit (whichever is longer), or plans to use an investigational drug (other than the study intervention) during the study.
- •Any medical, psychiatric, laboratory, or other condition that may negatively affect the benefit-risk considerations of study participation or interfere with the interpretation of study results and, in the judgment of the investigator and/or the medical monitor, would make the subject inappropriate for entry into this study.
- •Subjects not enrolling directly at the FALCON study completion visit (FALCON Week 48) or the safety follow-up visit (FALCON Week 53) study will be required to fulfill the additional exclusion criteria below during the screening visit:
- •General fatigue or muscle weakness due to causes other than mitochondrial disease, in the opinion of the investigator.
- •Subjects not enrolling directly at the FALCON study completion visit (FALCON Week 48) or the safety follow-up visit (FALCON Week 53) study will be required to fulfill the additional exclusion criteria below during the screening visit:
- •Significant cardiovascular disease (e.g., sustained or symptomatic arrhythmia, dilated heart chambers or reduced function, Mobitz II atrioventricular block or greater) OR abnormal ECG that is clinically significant, as determined by the investigator. Any QT interval corrected using Fridericia’s formula (QTcF) >450 msec for male subjects and >470 msec for female subjects is exclusionary. In the case of an exclusionary QTcF, the ECG can be repeated twice and the average of 3 QTcF intervals should be used to determine the QTcF eligibility.
- •Subjects not enrolling directly at the FALCON study completion visit (FALCON Week 48) or the safety follow-up visit (FALCON Week 53) study will be required to fulfill the additional exclusion criteria below during the screening visit:
- •Recent history of unstable disease, inadequately controlled neurological manifestations or not recovered from stroke-like episodes including but not limited to: a. stroke-like episodes within the last 6 months b. more than 1 seizure/month within the last 6 months c. hospitalized for Status Epilepticus within the last 6 months d. more than 4 days of migraine episodes/month within the last 6 months
- •Subjects not enrolling directly at the FALCON study completion visit (FALCON Week 48) or the safety follow-up visit (FALCON Week 53) study will be required to fulfill the additional exclusion criteria below during the screening visit:
- •History of inflammatory bowel disease, gastric erosions, peptic ulcer disease, or gastrointestinal bleeding episodes. Gastroesophageal reflux disease diagnosed by objective endoscopic or radiographic means, and clinically symptomatic at any point over the last 6 months.
- •Subjects not enrolling directly at the FALCON study completion visit (FALCON Week 48) or the safety follow-up visit (FALCON Week 53) study will be required to fulfill the additional exclusion criteria below during the screening visit:
- •The subject has 1 or more clinical laboratory test values outside the reference range, based on the blood and urine samples taken at the screening visit, that are of potential risk to the subject’s safety, or the subject has, at the screening visit: a. estimated glomerular filtration rate calculated by the Chronic Kidney Disease Epidemiology Collaboration creatinine equation <30 mL/min/1.73 m2 b. a serum total bilirubin value >1.5 times the upper limit of the reference range unless elevation is related to Gilbert’s syndrome and the investigator can rule out any underlying liver dysfunction based on other tests, the subject has a Child-Pugh score ≤6, and after discussing the case with the medical monitor c. a serum alanine aminotransferase (ALT) or aspartate aminotransferase (AST) value >2 times the upper limit of the reference range. Values between 2 and 3 times the upper limit of the reference range may be allowed if concomitant to elevation in creatine kinase as long as the investigator can rule out any underlying liver dysfunction based on other tests, the subject has a Child-Pugh score ≤6, and after discussing the case with the medical monitor
- •Subjects not enrolling directly at the FALCON study completion visit (FALCON Week 48) or the safety follow-up visit (FALCON Week 53) study will be required to fulfill the additional exclusion criteria below during the screening visit:
- •The subject has, in the investigator’s opinion, severe ataxia, neuropathy, balance problems, or other medical conditions that would interfere the evaluation of the 30s STS.
- •Subjects not enrolling directly at the FALCON study completion visit (FALCON Week 48) or the safety follow-up visit (FALCON Week 53) study will be required to fulfill the additional exclusion criteria below during the screening visit:
- •Untreated or undertreated sleep apnea, in the opinion of the investigator.
研究组 & 干预措施
null
Test
干预措施: null (Drug)
结局指标
主要结局
All safety parameters (including AEs, physical examination, vital signs, ECG, C-SSRS, and safety laboratory [hematology, blood chemistry, and urinalysis]).
All safety parameters (including AEs, physical examination, vital signs, ECG, C-SSRS, and safety laboratory [hematology, blood chemistry, and urinalysis]).
Occurrence of metabolic decompensation and lactic acidosis or image-verified stroke-like episodes consequent to GI AEs are AESIs and will be monitored throughout the study.
Occurrence of metabolic decompensation and lactic acidosis or image-verified stroke-like episodes consequent to GI AEs are AESIs and will be monitored throughout the study.
次要结局
- Other patient-reported outcomes: • EQ-5D-5L
- Patient-reported mitochondrial fatigue: • PROMIS® Fatigue PMD short form
- Functional outcome: • 30-second Sit-to-Stand Test
- Patient-reported lower extremity function: • Neuro-QOL Lower Extremity Function (Mobility) - short form
- Other patient-reported outcomes: • Patient Global Impression (multiple) - severity and change
- Global impression of severity of PMD disease expression: • Clinician Global Impression of PMD - severity and change
- Assessments of mitochondrial disease progression: • NMDAS, Subscales I-III
- Mitochondrial diabetes, subgroup analysis: • HbA1c (in subjects with diabetes)
研究者
Clinical Research Department
Scientific
Pharming Technologies B.V.
研究点 (35)
Loading locations...
相似试验
尚未招募
3 期
To study if iptacopan is safe, tolerable and effective in patients with aHUSCTRI/2024/07/070874Novartis Healthcare Pvt Ltd100
尚未招募
1 期
A Phase I Clinical Study of KSD-101 in Patients With Relapsed or Refractory EBV-associated Hematological MalignanciesRelapsed or Refractory EBV-associated Hematological MalignanciesNCT07532746Kousai Bio Co., Ltd.55
招募中
2 期
A Phase IIa, Single-arm, Open-label Clinical Study to Evaluate the Efficacy, Safety and PK of CVM-1118 in Combination With Sintilimab and TACE in Participants With Incurable/Non-metastatic HCCHCC - Hepatocellular CarcinomaNCT07521852TaiRx, Inc.40
招募中
3 期
Safety, Tolerability, Pharmacokinetics, and Efficacy of Filgotinib for the Treatment of Polyarticular-course Juvenile Idiopathic Arthritis in Children and AdolescentsPolyarticular Course Juvenile Idiopathic ArthritisNCT07554495Alfasigma S.p.A.65
招募中
1 期
U69-CART-Cells For R/R T-ALLNCT07350863The First Affiliated Hospital of Soochow University12